NCT00613327View on ClinicalTrials.gov

An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Oxybutynin chloride OROS

Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT00613327 - An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants | Biotech Hunter | Biotech Hunter